Telitacicept
Telitacicept is a pharmaceutical drug with 34 clinical trials. Currently 15 active trials ongoing. Historical success rate of 60.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
8
Mid Stage
19
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
50.0%
3 of 6 finished
50.0%
3 ended early
15
trials recruiting
34
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Chinese Adults With Kidney Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Treatment Strategy for Patients With RA-ILD
Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Clinical Trials (34)
Chinese Adults With Kidney Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Treatment Strategy for Patients With RA-ILD
Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
Telitacicept in Primary APS Patients
Telitacicept for the Treatment of Refractory RA
Study of Telitacicept in Generalized Myasthenia Gravis
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 34